<?xml version="1.0" encoding="iso-8859-1"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>HHS/OIG-Audit--&quot;Cost of Dialysis-Related Drugs, (A-01-91-00526)&quot;</title>
<meta name="Keywords" content="Audit Report, HHS Office of Inspector General, Office of Audit Services (OAS), End Stage Renal Disease/Dialysis, Medicare, Centers for Medicare and Medicaid Services (CMS), Drugs" />
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1" />
</head>




<body>

<!-- Google Tag Manager -->
<noscript><iframe src="//www.googletagmanager.com/ns.html?id=GTM-JLFR"
height="0" width="0" style="display:none;visibility:hidden" title="googletagmanager"></iframe></noscript>
<script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({"gtm.start":new Date().getTime(),event:"gtm.js"});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!="dataLayer"?"&l="+l:"";j.async=true;j.src="//www.googletagmanager.com/gtm.js?id="+i+dl;f.parentNode.insertBefore(j,f);})(window,document,"script","dataLayer","GTM-JLFR");</script>
<!-- End Google Tag Manager -->


 


<a href="#content"><img src="/images/skip_pixel.gif" alt="Skip to Content" style="border:0 !important" /></a>
<h2><a name="content"></a><em><!-- #BeginLibraryItem "/Library/top anchor.lbi" --><a name="top" id="top"></a><!-- #EndLibraryItem -->Department
    of Health and Human Services</em></h2>
<h3>Office of Inspector General -- AUDIT </h3>
<h3>&quot;Cost of Dialysis-Related Drugs,&quot; (A-01-91-00526) </h3>
<h3>October 20, 1992</h3>
<hr noshade="noshade" />
<h5><a href="19100526.pdf">Complete
    Text of Report </a>is available in PDF format (1.37 MB). Copies can also be obtained by contacting the Office of Public
    Affairs at 202-619-1343.</h5>
<hr noshade="noshade" />
<p><strong>EXECUTIVE SUMMARY:</strong></p>
<p>This final report summarizes the results of our review of the Health Care Financing Administration's (HCFA) proposal to
  change the methodology for reimbursing separately billable drugs under Medicare's end stage renal disease (ESRD) program.
  Our results indicated that dialysis facilities purchase separately billable drugs significantly below the average wholesale
  price. </p>
<!-- #BeginLibraryItem "/Library/bottom.lbi" -->

<!-- #EndLibraryItem --></body>
</html>
